Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol Title: A Phase 2 Open-label Study to Evaluate the Safety and Pharmacokinetics of MK-8527 Oral Once-monthly in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of HIV-1 Exposure

NCT07850609 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT07850609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol Title: A Phase 2 Open-label Study to Evaluate the Safety and Pharmacokinetics of MK-8527 Oral Once-monthly in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of HIV-1 Exposure
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 29, 2026
Completion date
December 2, 2027
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv